Back to top

Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies

In a report released today, from Jefferies maintained a Buy rating on Supernus Pharmaceuticals, with a price target of $65.00. Currently, the analy...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Supernus Pharmaceuticals, Inc. (SUPN)